A new once-daily weight loss pill, Foundayo, reached pharmacies across the UK on Monday. Manufactured by Eli Lilly, the medication orforglipron marks a shift in obesity management by offering an oral alternative to the existing injectable options.
Approval and Regulatory Context
The UK leads Europe in making this drug available to the public. The Medicines and Healthcare products Regulatory Agency granted authorization for the medication earlier this month. This event arrives following the introduction of other GLP-1 weight loss treatments, such as Wegovy, which hit the market in July.
Regulatory bodies currently assess the drug for inclusion in the National Health Service. Eli Lilly representatives are working with the National Institute for Health and Care Excellence to determine if the medication will receive coverage under the public health system. Until that decision arrives, patients must rely on pharmacy availability.
Clinical Applications and Usage
Foundayo is licensed for adults who meet specific clinical criteria. It is intended for individuals with a body mass index of 30 or higher. Those with a body mass index between 27 and 30 are also eligible if they suffer from at least one weight-related condition. Beyond weight reduction, the drug shows potential for blood sugar improvement in patients with poorly controlled type 2 diabetes.
Patients take the pill once a day. Manufacturers state that there are no restrictions regarding food or water intake when taking the medication. The treatment plan follows a specific dosage ramp-up, beginning at 0.8mg and increasing through several stages up to 17.2mg. Each dosage level requires a minimum of one month for the patient to adjust. This staged approach allows clinicians to monitor the bodily response to the medication over time.
Industry and Patient Perspectives
Pharmacy leaders view this release as a necessary step for those who cannot or will not use injection-based treatments. Henry Gregg, the chief executive of the National Pharmacy Association, noted that this change makes medical weight loss support accessible to a wider pool of patients. He emphasized that the availability of oral medication in regulated pharmacies is safer than unregulated channels.
Criminal actors often exploit demand for weight loss drugs by selling fake or counterfeit versions of these products online. Regulators and industry figures now urge patients to use only official, licensed pharmacies for their prescriptions. This push for safety arrives alongside broader calls for the NHS to improve the current distribution of weight management services across the country. Patients currently face significant regional variation in access to care, a situation often described as a postcode lottery by health advocates.